SHC
Sotera Health Company16.70
-0.10-0.6%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.74BP/E (TTM)
83.50Basic EPS (TTM)
0.20Dividend Yield
0%Recent Filings
8-K
Strong Q3 revenue surge
Sotera Health reported robust Q3 2025 results, with net revenues up 9.1% to $311 million and Adjusted EBITDA rising 12.2% to $164 million, fueled by strong volume growth at Sterigenics and Nordion despite a dip at Nelson Labs. Year-to-date, revenues climbed 6.2% to $860 million, though net income reflects $65 million in EO litigation settlements. The company raised its full-year Adjusted EBITDA growth outlook to 6.75%-7.75% on constant currency, signaling confidence amid supply chain risks. Debt costs fell after refinancing.
10-Q
Q3 FY2025 results
Sotera Health posted solid Q3 results, with net revenues climbing 9.1% year-over-year to $311.3 million, fueled by volume growth in Sterigenics and Nordion while Nelson Labs dipped on softer advisory services. Gross profit jumped 12.4% to $177.6 million, lifting margins to 57.0% from 55.4%, thanks to pricing gains and efficiency tweaks that outpaced inflation. Operating income soared 71.1% to $72.9 million (derived), and diluted EPS rose to $0.17 from $0.06, aligning neatly with 286.7 million shares. Cash from operations hit $184.1 million year-to-date, funding $87.3 million in capex and a $75 million term loan paydown; free cash flow stood at $96.8 million (derived), with $299.2 million in cash and $591.9 million revolver availability backing $2.1 billion in debt at 6.91%. Revenue relies heavily on two Nordion clients. Yet EO litigation lingers as a wildcard.
8-K
Sotera Health Company has refinanced its term loans through Amendment No. 6 to its First Lien Credit Agreement, effective September 17, 2025. The amendment replaces existing term loans with new Repriced Term Loans totaling $1,423,029,875, featuring a reduced interest rate spread of 0.50% over Adjusted Term SOFR, a 1.00% prepayment premium for certain repricing transactions within six months, and a maturity date of May 30, 2031. This refinancing enhances the company's capital structure by lowering borrowing costs and extending debt maturities, supporting ongoing operations and strategic initiatives without altering revolving commitments.
Sotera Health Company has refinanced its term loans through Amendment No. 6 to its First Lien Credit Agreement, effective September 17, 2025. The amendment replaces existing term loans with new Repriced Term Loans totaling $1,423,029,875, featuring a reduced interest rate spread of 0.50% over Adjusted Term SOFR, a 1.00% prepayment premium for certain repricing transactions within six months, and a maturity date of May 30, 2031. This refinancing enhances the company's capital structure by lowering borrowing costs and extending debt maturities, supporting ongoing operations and strategic initiatives without altering revolving commitments.
8-K
Selling stockholders dump 20M shares
Sotera Health's selling stockholders offloaded 20 million shares of common stock at $15.111 each through Goldman Sachs on September 5, 2025, following an agreement signed September 3. The company issued no new shares and pockets nothing from the $302.22 million deal. No impact on Sotera's capital structure.
8-K
Strong Q2 results, raised outlook
Sotera Health reported Q2 2025 net revenues up 6.4% to $294 million, driven by strong Sterigenics volume growth of 10.5%, while Adjusted EBITDA rose 9.8% to $151 million amid margin gains at Nelson Labs. Yet a $34 million EO litigation settlement dragged net income to $8 million. The company raised its full-year outlook, targeting 4.5%-6.0% revenue growth and 6.0%-7.5% Adjusted EBITDA growth on constant currency. Litigation costs persist.
IPO
Website
Employees
Sector
Industry
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
GH
Guardant Health, Inc.
100.00-2.67
LH
Labcorp Holdings Inc.
258.11-5.22
NDRA
ENDRA Life Sciences Inc.
4.94-0.37
NEO
NeoGenomics, Inc.
11.67-0.25
NOTV
Inotiv, Inc.
0.68-0.02
SERA
Sera Prognostics, Inc.
3.56+0.18
SRXH
SRX Health Solutions, Inc.
0.38+0.07
STE
STERIS plc (Ireland)
253.03-1.04